Experimental weight-loss drug cuts knee pain in half for arthritis patients

An experimental injectable weight-loss medication called retatrutide significantly reduced knee pain in people with osteoarthritis, according to two major clinical trials. ScienceDaily Health reported that roughly two-thirds of participants who received the highest dose experienced at least a 50% reduction in knee pain, compared to 38% of those given a placebo.
The trials, led by Northwestern University, included more than 1,000 participants in total. People receiving the highest dose of retatrutide lost an average of about 25% of their body weight. The findings were published on Nov. 8 in the New England Journal of Medicine.
Beyond weight loss and pain relief, participants also showed reductions in blood pressure, blood lipid levels, and inflammation throughout the body, according to ScienceDaily Health. A Northwestern researcher noted that losing significant weight reduces stress on the knees, which decreases pain and allows people to increase their physical activity.
However, the research does not yet show whether retatrutide can prevent further joint damage in people with knee osteoarthritis, ScienceDaily Health reported. The drug remains experimental and has not been approved for this use.
What it means in Raleigh
Behavioral health: Alliance Health (LME/MCO for Wake, Durham, Johnston, Orange, Cumberland, Mecklenburg)
Medicaid plans: NC Medicaid Standard Plans: AmeriHealth Caritas NC, Carolina Complete Health, Healthy Blue, UnitedHealthcare Community Plan, WellCare of NC. Tailored Plans: Alliance Health, Partners Health Management, Trillium Health Resources, Vaya Health.
Major insurers: Blue Cross NC, Aetna, Cigna, UnitedHealthcare, Humana
Plan lists change; confirm with your plan or the state agency.